DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe Hypertension

Information source: Novartis
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: aliskiren (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Novartis

Official(s) and/or principal investigator(s):
Novartis Pharmaceuticals, Study Director, Affiliation: Novartis Pharmaceuticals


To compare the safety and efficacy of an aliskiren-based regimen to a lisinopril-based regimen in the treatment of severe hypertension

Clinical Details

Official title: An Eight-week, Randomized, Double-blind, Multi-center, Active-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of an Aliskiren-based Regimen Compared to a Lisinopril-based Regimen in Patients With Uncomplicated Severe Hypertension

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: Evaluate safety through adverse events and laboratory abnormalities after 8 weeks

Secondary outcome:

Change from baseline in diastolic blood pressure after 8 weeks

Change from baseline in systolic blood pressure after 8 weeks

Change from baseline in standing systolic blood and diastolic pressure after 8 weeks

Diastolic blood pressure is less than 90 mmHg or reduction of 10 mmHg or greater from baseline after 8 weeks


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria

- Patients with essential severe hypertension Exclusion Criteria

- History or evidence of a secondary form of hypertension

- History of hypertensive encephalopathy or cerebrovascular accident.

- Diabetic patients requiring insulin Other protocol-defined inclusion/exclusion

criteria also apply

Locations and Contacts

Investigative Site, Berlin, Germany

Investigative Site, Budapest, Hungary

Investigative Site, Madrid, Spain

Novartis Pharmaceuticals, Basel, Switzerland

Additional Information

Starting date: February 2005
Last updated: February 24, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017